Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure

Barrington Philip; Sheetz Matthew J.; Callies Sophie; Waters D. G.; Berg Paul H.; Pappas Donna; Marbury Thomas C.; Decker Brian S.; Berg Jolene Kay

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure

【24h】

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure

机译：慢性肾功能衰竭贫血患者中抗铁转运蛋白抗体的安全性，耐受性，药代动力学和药效动力学

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Barrington Philip; Sheetz Matthew J.; Callies Sophie; Waters D. G.; Berg Paul H.; Pappas Donna; Marbury Thomas C.; Decker Brian S.; Berg Jolene Kay;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure [J] . Barrington Philip, Sheetz Matthew J., Callies Sophie, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：慢性肾功能衰竭贫血患者中抗铁转运蛋白抗体的安全性，耐受性，药代动力学和药效动力学
2. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma [J] . Massard Christophe, Soria Jean-Charles, Krauss Juergen, Cancer chemotherapy and pharmacology. . 2019,第6期

机译：在复发/难治性肾细胞癌患者中评估抗CD27L抗体 - 药物缀合物AMG 172的安全性，耐受性，药代动力学和药效动物的第一人体研究
3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis [J] . WisniackiN., AmaravadiL., GalluppiG.R., Clinical therapeutics . 2013,第8期

机译：类风湿性关节炎患者抗调节单克隆抗体的安全性，耐受性，药代动力学和药效学
4. Safety, tolerability, pharmacodynamics and pharmacokinetics following single subcutaneous dosesof a teverelix depot formulation in healthy male volunteers [C] . C. MacLean, F. Larsen, R. Piechatzek, Annual meeting exposition of the Controlled Release Society . 2005

机译：在健康男性志愿者中单次皮下注射Teverelix储库制剂后的安全性，耐受性，药效动力学和药代动力学
5. The safety and tolerability of regadenoson in patients with end stage renal disease. [D] . Rangel, Maria Octavia. 2013

机译：regadenoson在晚期肾病患者中的安全性和耐受性。
6. Safety tolerability pharmacokinetics and pharmacodynamics of the afucosylated humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors [O] . Kohei Shitara, Taroh Satoh, Satoru Iwasa, 2019

机译：无岩藻糖基化的人源化抗EPHA2抗体DS-8895a的安全性耐受性药代动力学和药效学：在患有晚期实体瘤的患者中进行的人体内第一阶段I剂量递增和剂量扩展研究
7. FP396A PROSPECTIVE OBSERVATIONAL STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF IRON ISOMALTOSIDE 1000 IN THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE [O] . Frank Leistikow, Andreas Walper, Richard Ammer, 2015

机译：FP396A预期观测研究铁异麦托苷的疗效，安全性和可耐药性1000在慢性肾功能衰竭患者患者的治疗中治疗缺铁性贫血

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure

著录项

相似文献

相关主题

期刊订阅